[What are the indications for treatment of acute hepatitis C?].
Service d'Hépato-Gastroentérologie, Groupe Hospitalier Pitié-Salpêtrière, Paris.
Robert P
RP
Myers
Corinne
C
Regimbeau
Joseph
J
Moussalli
Vlad
V
Ratziu
Vincent
V
Di Martino
Dominique
D
Thabut
Brigitte
B
Bernard
Yves
Y
Benhamou
Thierry
T
Poynard
D000208:Acute Disease; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D004796:Clinical Enzyme Tests; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy* / Q000635:transmission; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D016899:Interferon-beta / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D019966:Substance-Related Disorders / Q000150:complications; D013997:Time Factors; D000637:Transaminases / Q000097:blood; D065227:Transfusion Reaction
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin; D016899:Interferon-beta; D000637:Transaminases